Mostrar o rexistro simple do ítem

dc.contributor.authorPuente, Javier
dc.contributor.authorLainez, Nuria
dc.contributor.authorDueñas, Marta
dc.contributor.authorMéndez-Vidal, María José
dc.contributor.authorEsteban, Emilio
dc.contributor.authorCastellano, Daniel
dc.contributor.authorMartínez-Fernández, Mónica
dc.contributor.authorBasterretxea, Laura
dc.contributor.authorJuan-Fita, María José
dc.contributor.authorAntón-Aparicio, Luis M.
dc.contributor.authorLeón, Luis
dc.contributor.authorLambea, Julio
dc.contributor.authorPérez-Valderrama, Begoña
dc.contributor.authorVázquez, Sergio
dc.contributor.authorSuárez, Cristina
dc.contributor.authorGarcía del Muro, Xavier
dc.contributor.authorGallardo, Enrique
dc.contributor.authorMaroto, José Pablo
dc.contributor.authorSamaniego, M. Luz
dc.contributor.authorSuárez-Paniagua, Beatriz
dc.contributor.authorSanz, Julián
dc.contributor.authorParamio, Jesús M.
dc.date.accessioned2018-09-21T08:08:44Z
dc.date.available2018-09-21T08:08:44Z
dc.date.issued2017-03-23
dc.identifier.citationPuente J, Laínez N, Dueñas M, Méndez-Vidal MJ, Esteban E, Castellano D, et al. Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma. Oncotarget. 2017;8(18):30410-30421es_ES
dc.identifier.issn1949-2553
dc.identifier.urihttp://hdl.handle.net/2183/21038
dc.description.abstract[Abstract] Background: Several potential predictive markers of efficacy of targeted agents in patients with metastatic renal cell carcinoma (mRCC) have been identified. Interindividual heterogeneity warrants further investigation. Patients and methods: Multicenter, observational, retrospective study in patients with clear-cell mRCC treated with sunitinib. Patients were classified in two groups: long-term responders (LR) (progression-free survival (PFS)≥22 months and at least stable disease), and primary refractory (PR) (progressive disease within 3-months of sunitinib onset). Objectives were to compare baseline clinical factors in both populations and to correlate tumor expression of selected signaling pathways components with sunitinib PFS. Results: 123 patients were analyzed (97 LR, 26 PR). In the LR cohort, overall response rate was 79% and median duration of best response was 30 months. Median PFS and overall survival were 43.2 (95% confidence intervals[CI]:37.2-49.3) and 63.5 months (95%CI:55.1-71.9), respectively. At baseline PR patients had a significantly lower proportion of nephrectomies, higher lactate dehydrogenase and platelets levels, lower hemoglobin, shorter time to and higher presence of metastases, and increased Fuhrman grade. Higher levels of HEYL, HEY and HES1 were observed in LR, although only HEYL discriminated populations significantly (AUC[ROC]=0.704; cut-off=34.85). Increased levels of hsa-miR-27b, hsa-miR-23b and hsa-miR-628-5p were also associated with prolonged survival. No statistical significant associations between hsa-miR-23b or hsa-miR-27b and the expression of c-Met were found. Conclusions: Certain mRCC patients treated with sunitinib achieve extremely long-term responses. Favorable baseline hematology values and longer time to metastasis may predict longer PFS. HEYL, hsa-miR-27b, hsa-miR-23b and hsa-miR-628-5p could be potentially used as biomarkers of sunitinib response.es_ES
dc.description.sponsorshipPPfizer; SOGUG-2011-05es_ES
dc.description.sponsorshipMinisterio de Economía, Industria y Competitividad; SAF2015-66015-Res_ES
dc.description.sponsorshipMinisterio de Economía, Industria y Competitividad; ISCIII-RETIC RD12/0036/0009es_ES
dc.description.sponsorshipMinisterio de Economía, Industria y Competitividad; PIE 15/00076es_ES
dc.language.isoenges_ES
dc.publisherImpact Journalses_ES
dc.relation.urihttps://doi.org/10.18632/oncotarget.16494es_ES
dc.rightsAtribución 3.0 Españaes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectBiomarkeres_ES
dc.subjectLong-term responderses_ES
dc.subjectMetastatic renal cell carcinomaes_ES
dc.subjectPrimary refractoryes_ES
dc.subjectSunitinibes_ES
dc.titleNovel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinomaes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessinfo:eu-repo/semantics/openAccesses_ES
UDC.journalTitleOncotargetes_ES
UDC.volume8es_ES
UDC.issue18es_ES
UDC.startPage301410es_ES
UDC.endPage30421es_ES


Ficheiros no ítem

Thumbnail
Thumbnail

Este ítem aparece na(s) seguinte(s) colección(s)

Mostrar o rexistro simple do ítem